What is Bretisilocin?
Bretisilocin (GM-2505) is an investigational psychedelic compound in Phase 2 development for major depressive disorder (MDD). It acts as a short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser.
Yanuki
ARTICLE DETAIL
AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder | USA Starts Strong in World Baseball Classic | USA vs. Great Britain: World Baseball Classic 2026 Preview | USWNT SheBelieves Cup 2026: Title Hopes and Team Updates | Shohei Ohtani's Grand Slam Leads Japan to WBC Victory | USA vs. Brazil: World Baseball Classic 2026 Opener | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder | USA Starts Strong in World Baseball Classic | USA vs. Great Britain: World Baseball Classic 2026 Preview | USWNT SheBelieves Cup 2026: Title Hopes and Team Updates | Shohei Ohtani's Grand Slam Leads Japan to WBC Victory | USA vs. Brazil: World Baseball Classic 2026 Opener | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy'
Health / Mental Health
AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder
AbbVie (NYSE: ABBV) has acquired Gilgamesh Pharmaceuticals' Bretisilocin, a novel investigational therapy for major depressive disorder (MDD), for up to $1.2 billion. This acquisition significantly expands AbbVie's psychiatry pipeline and u...
Key Insights
- Bretisilocin (GM-2505) is a short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser.
- Phase 2a study results showed a clinically impactful and statistically significant reduction in depressive symptoms compared to a low-dose active comparator.
- At Day 14, a single 10mg dose of bretisilocin demonstrated a -21.6 point change from baseline in MADRS total score compared to a -12.1 point change for the comparator (p = 0.003).
- AbbVie's acquisition includes an upfront payment and development milestones, with Gilgamesh spinning off a new entity, Gilgamesh Pharma Inc.
In-Depth Analysis
AbbVie's move to acquire Gilgamesh's Bretisilocin program highlights the growing interest in psychedelic compounds as potential treatments for mental health disorders. Bretisilocin's unique mechanism of action, targeting the 5-HT2A receptor, has shown promise in early clinical trials.
The Phase 2a study demonstrated a robust antidepressant effect with a single dose, indicating the potential for rapid symptom relief. The drug was also well-tolerated, with no serious adverse events reported. This acquisition builds upon a previous collaboration between AbbVie and Gilgamesh, further solidifying their partnership in developing next-generation therapies for psychiatric disorders.
Gilgamesh Pharma Inc., the spun-off entity, will continue to advance other programs, including blixeprodil (GM-1020), an oral NMDA receptor antagonist, and a cardio-safe ibogaine analog.
FAQ
How effective is Bretisilocin?
In a Phase 2a study, a single 10mg dose of bretisilocin demonstrated a significant reduction in depressive symptoms compared to a low-dose active comparator.
What is AbbVie's interest in Bretisilocin?
AbbVie aims to broaden and enhance psychiatric care by investing in novel treatment approaches for patients who have not responded to other treatments.
Takeaways
- AbbVie's acquisition of Bretisilocin signals a growing interest in psychedelic therapies for major depressive disorder.
- Bretisilocin has shown promising results in early clinical trials, with a rapid and significant reduction in depressive symptoms.
- The drug's shorter duration of psychoactive experience may offer advantages over existing psychedelic agents.
- This acquisition could lead to the development of new and more effective treatments for individuals struggling with MDD.
Discussion
Do you think psychedelic therapies will become a mainstream treatment for mental health disorders? Let us know in the comments below!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.